TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03734705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure Writing
Description: Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral Writing
Description: Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
Study: NCT04609878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/28.8/9.6 μg
Description: Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
Study: NCT02328469

Intervention type: DRUG
Intervention: symptomatic therapy
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline

Intervention type: DRUG
Intervention: symptomatic therapy
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline

Intervention type: DRUG
Intervention: Ceftriaxone or Doxycycline
Description: beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days

Intervention type: OTHER
Intervention: questionnaire
Description: Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

Intervention type: OTHER
Intervention: questionnaire
Description: Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

Intervention type: OTHER
Intervention: questionnaire
Description: Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

Intervention type: OTHER
Intervention: questionnaire
Description: Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

Intervention type: OTHER
Intervention: questionnaire
Description: Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

Intervention type: DRUG
Intervention: Acyclovir
Description: Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
Study: NCT00689988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech-language therapy with AAC intervention
Description: speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
Study: NCT02757495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
Study: NCT01186432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS 1.0
Study: NCT00499265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serine Proteinase Inhibitor WX-671
Description: oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serine Proteinase Inhibitor WX-671
Description: oral, daily
Study: NCT02449330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Study: NCT00002850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofloxacin
Description: Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg trimethoprim and 800 mg sulfamethoxazole
Description: Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\] every 12 hours for two months..
Study: NCT01939795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training and/or CRT
Description: Three 40-minute exercise sessions per week on a treadmill for four months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training and/or CRT
Description: Three 40-minute exercise sessions per week on a treadmill for four months
Study: NCT02001740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinalone (steroid) and lidocaine
Description: receive once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: receive once
Study: NCT02680067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
Study: NCT03683901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Electrical Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t-NMES
Description: Electrical Stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No stimulation
Description: No stimulation
Study: NCT04787458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdomen binder (Sejung Korea, Seoul, Republic of Korea)
Description: abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
Study: NCT01293877

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy surgery for morbid obesity
Description: The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy surgery for morbid obesity
Description: The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
Study: NCT02746939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InSciEd Out Fitness and Nutrition Curriculum
Description: Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
Study: NCT04234230

Intervention type: OTHER
Intervention: Prevalence Survey
Description: Questionnaire survey on self-management
Study: NCT00855478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher stent ™ or Cypher Select ™
Description: Cypher drug-eluting stent
Study: NCT01995357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a newly developed ostomy appliance
Study: NCT02908321

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
Study: NCT02890186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcotrend
Description: the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
Study: NCT02680067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSpectral Imaging System
Description: Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
Study: NCT03968146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Study: NCT02890186

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: experience
Description: the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
Study: NCT04609878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BFF MDI 320/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BFF pMDI 320/9 μg
Description: Budesonide/formoterol fumarate pressurized metered dose inhaler
Study: NCT05468476

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00834535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir Capsules 300 mg
Description: 1 x 300 mg, single-dose non-fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMNICEF® Capsule 300 mg
Description: 1 x 300 mg, single-dose non-fasting
Study: NCT02359825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Description: For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Description: For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Description: For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
Study: NCT04250545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO
Study: NCT01995357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard product
Description: Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard product
Description: Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard product
Description: Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard product
Description: Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard product
Description: Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard product
Description: Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
Study: NCT01155388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Experimental: Ferumoxytol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Active Comparator: Oral iron
Study: NCT03312465

Intervention type: DEVICE
Intervention: AS Domelock System
Description: Hemi or Total Shoulder Arthroplasty
Study: NCT03841825

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions and motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions and motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions and motivation
Study: NCT03968146

Intervention type: DRUG
Group type: OTHER
Intervention: additional Fentanyl
Description: patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
Study: NCT03620903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib / Bortezomib / Rituximab
Description: Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
Study: NCT01718236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium + sugammadex
Description: Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine + Neostigmine
Description: 1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
Study: NCT03968146

Intervention type: DRUG
Group type: OTHER
Intervention: rescue Morphine
Description: Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue Morphine
Description: Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.

Intervention type: DRUG
Group type: OTHER
Intervention: pethidine
Description: After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine
Description: After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac
Description: patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Study: NCT03701503

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women
Study: NCT02936895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D at a dose of 50,000 IU per day for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 2 days
Study: NCT00631462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG101348
Description: Orally administered, once a day, for 28 days, up to 6 cycles.